摘要
目的分析瑞舒伐他汀治疗高脂血症后不同疗效的患者肠道微生态菌群的差异。方法将本院68例行瑞舒伐他汀治疗的高脂血症患者作为研究对象,根据患者治疗后2个月降脂效果的不同,分为降脂良好组(A组,n=49)与降脂欠佳组(B组,n=19)。比较两组患者治疗前后血脂水平的差异,并收集患者粪便提取肠道微生态菌群DNA,采用DNA测序技术分析患者肠道微生态菌群的差异。结果 A组治疗后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白-胆固醇(LDL-C)的含量较治疗前均明显下降,高密度脂蛋白-胆固醇(HDL-C)含量较治疗前明显升高,且治疗后A组与B组比较TC、TG、LDL-C的含量均明显下降,HDL-C含量明显升高(P <0. 05)。A组疣微菌门、厚壁菌门、梭杆菌门及柔壁菌门丰度较B组显著升高,而互养菌门、蓝细菌门、放线菌门及拟杆菌门丰度较B组显著下降(P <0. 05)。A组拟杆菌门中的拟杆菌科的相对丰度较B组明显减少(P <0. 05);厚壁菌门中的乳酸杆菌科、毛螺菌科、瘤胃菌科和梭菌科的相对丰度较B组均明显增多(P <0. 05)。结论采用瑞舒伐他汀治疗高脂血症后,不同疗效差异的患者在肠道微生态菌群门丰度和科数量方面存在较大差异。
Objective To analyze the differences of intestinal microbial flora in patients with hyperlipidemia treated with rosuvastatin. Methods 68 patients with hyperlipidemia who were treated with rosuvastatin in our hosdspital were enrolled. According to the differences of lipid-lowering effect in 2 months after treatment,group A(49 cases) had good lipid-lowering effect and group B(19 cases) had poor lipid-lowering effect. The differences of blood lipid levels between the two groups before and after treatment were compared. The faeces of the patients were collected and DNA of intestinal microflora was extracted.The differences of intestinal microflora were analyzed by DNA sequencing. Results After treatment,the contents of total cholesterol(TC),triglyceride(TG) and low-density lipoprotein cholesterol(LDL-C) in group A were significantly lower than those before treatment,while the contents of high-density lipoprotein-cholesterol(HDL-C) were significantly higher than those before treatment,and the contents of TC,TG and LDL-C in group A were significantly lower than those in group B after treatment,HDL-C in group B increased significantly(P < 0. 05). The abundance of microflora,sclerenchyma,fusobacterium and flexneria in group A was significantly higher than that in group B,while the abundance of synergistetes,cyanobacteria,actinomycetes and bacteroides in group A was significantly lower than that in group B(P < 0. 05). The relative abundance of bacteroides in group A was significantly lower than that in group B(P < 0. 05),and the relative abundance of Lactobacillus,trichomonas,ruminococcaceae and clostridium in sclerenchyma was significantly higher than that in group B(P <0. 05). Conclusions There are significant differences in the abundance and number of families of intestinal microflora in patients with hyperlipidemia treated with rosuvastatin.
作者
张玲
陈雪梅
ZHANG Ling;CHEN Xue-mei(Hanzhong People’s Hospital,Shanxi 723000,China)
出处
《心脑血管病防治》
2019年第5期408-410,414,共4页
CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT